This poster was presented at HBV meeting 2025

Abstract. We undertook a point-of-care test (POCT) for hepatitis B core-related antigen (HBcrAg) on adults living with HBV in Kilifi, Kenya. A positive tes

We are a team of clinicians and researchers based at the Francis Crick Institute in London, and working with international partners and collaborators to advance progress towards hepatitis B eliminatio...

HBcrAg-RDT might offer a practical solution for integrating the prevention of vertical transmission of HBV into decentralised antenatal care in resource-limited settings, enabling timely identificatio...

Do you enjoy using science to drive change in the world? Would you like to develop and launch an online-only gold open access journal for The Lancet. About our Team The Lancet Regional Health -Africa ...

The sudden freezing of USAID funds is jeopardising the goal of eliminating viral hepatitis by 2030. In an editorial published 14 February, the Lancet Gastroenterology & Hepatology said efforts to …

Sparked by a flurry of executive orders in the first week of taking power, and evolving at dizzying pace, the new US administration has taken a wrecking ball to health-related services and research bo...

We are facing a new threat to global health.

In addition to goals of reducing tuberculosis incidence by 80% and tuberculosis deaths by 90% worldwide by 2030, the WHO End TB Strategy aims to eliminate catastrophic costs—defined as out-of-pocket expenses that exceed 20% of annual household income—for households affected by tuberculosis by 2030.1 In this Comment, we consider this concept for people living with hepatitis B.